3 assets in Inborn Mitochondrial Metabolism Disorder

Therapeutic assets addressing Inborn Mitochondrial Metabolism Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pioglitazone Inborn Mitochondrial Metabolism Disorder	The University of Texas Health Science Center at San Antonio	P4	BB (64)
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione Inborn Mitochondrial Metabolism Disorder	Kenneth Myers, MD	P2	CCC (53)
Doxecitine Inborn Mitochondrial Metabolism Disorder	Kenneth Myers, MD	P2	CCC (53)